Re: Liz.. Ot

[Guest guest]

I know darlin and thats why I worry about you and so want you to be able to do treatment and reach SVR,, before you reach that point!Jackie

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

Yeah it does and thats why Im sooo hoping you can treat and reach SVR... with grade of 4, you know its munching on your liver big time... I hope your doc will let you treat this time and that you will be able to tolerate it better than the times before... and I hope you will have enough help at home so that you wont have anything to worry about except staying on tx..Jackie

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

I am keeping my fingers crossed . They aren't don't with the final pathology , just hope they dont find anything else in there ...

[Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

Well I am getting my iron down and that should help ,

[Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

Thats true Sheena,, I just SOOO want her to reach SVR before she hits ESLD.. thats all..Jackie

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with

nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in

mice

with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study

coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

I think we all agree on that..

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with

nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice

with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study

coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

Geeeeeezzz, Louise, that is a long ways off!

I see hepatologist in Dec .. he will not be here til then

Re: [Hepatitis_C_ Central] Liz.. Ot

When do you see your GI again?

--- On Wed, 8/27/08, elizabethnv1 <elizabethnv1@ earthlink. net> wrote

I think that is why they wanted me to get the biopsy , to see if I need to treat now or can wait longer

Recent Activity

3

New Members

1

New PhotosVisit Your Group

Meditation and

Lovingkindness

A Yahoo! Group

to share and learn.

Yahoo! Health

Achy Joint?

Common arthritis

myths debunked.

New web site?

Drive traffic now.

Get your business

on Yahoo! search.

..

[Guest guest]

His primary office is in San Fransisco , so he only comes here for a few days a month and is booked solid til then ..

Re: [Hepatitis_C_ Central] Liz.. Ot

When do you see your GI again?

--- On Wed, 8/27/08, elizabethnv1 <elizabethnv1@ earthlink. net> wrote

I think that is why they wanted me to get the biopsy , to see if I need to treat now or can wait longer

Recent Activity

3

New Members

1

New PhotosVisit Your Group

Meditation and

Lovingkindness

A Yahoo! Group

to share and learn.

Yahoo! Health

Achy Joint?

Common arthritis

myths debunked.

New web site?

Drive traffic now.

Get your business

on Yahoo! search.

..

[Guest guest]

thats good,, altho being slightly anemic will make you feel like warmed over doo doo while ton tx,, I sure hope you make it this time honJackie

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with

nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice

with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study

coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

well WE will ALL keep our fingers crossed for you!Jackie

From: <elizabethnv1@ earthlink. net>Subject: [Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with

nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice

with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study

coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

Somehow I don't think they will ever let me try it again .... but I push and push lol

[Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

xoxo

[Hepatitis_C_ Central] Anticoagulant Drug Warfarin May Slow Liver Fibrosis ProgressionTo: Hepatitis_C_ Central@yahoogro ups.comDate: Tuesday, August 26, 2008, 2:08 AM

Anticoagulant Drug Warfarin May Slow Liver Fibrosis Progression

By Liz Highleyman

Over the course of years or decades, people with chronic viral hepatitis may progress to advanced liver disease, including severe fibrosis or cirrhosis. Some studies indicate that this may occur faster in HIV positive patients coinfected with hepatitis B or C.Successful treatment with nucleoside/nucleoti de analogs for hepatitis B or interferon-based therapy for hepatitis C can slow or halt liver disease progression. However, such treatment is not always successful over the long term, and investigators have also studied therapies aimed at directly interfering with the fibrosis process.

Warfarin Tablets

The blood-thinning drug warfarin, used as an anticoagulant to reduce blood clotting, might play a role in limiting fibrosis, according to British study described in the August 2008 Journal of Thrombosis and Haemostasis.As background, the study authors noted that there is evidence that activation of the coagulation system contributes to wound healing and promotes organ fibrosis, both of which involve production of collagen and other substances that make up scar tissue. Several epidemiological studies have shown that a pro-thrombotic state, including presence of the factor V Leiden mutation, is associated with rapid liver fibrosis progression.

The aim of the present study was to assess the effect of a pro-coagulant state on progression of liver fibrosis in a controlled laboratory environment, and to test whether an anticoagulant agent could reduce fibrogenesis. The investigators analyzed the effects of coagulation status on fibrosis progression in a mouse model of chronic liver injury. Mice with the prothrombotic factor V Leiden mutation, "anticoagulated" mice, and control mice were exposed to carbon tetrachloride, which produces liver damage similar to that seen in people with drug-induced hepatotoxicity, excessive alcohol use, chronic viral hepatitis, and other liver conditions.The researchers found that mice carrying the factor V Leiden mutation had significantly increased hepatic fibrosis. The anticoagulant warfarin significantly reduced fibrosis progression in wild-type (non-mutant) mice, but was less effective in mice with the profibrotic FV Leiden mutation. Changes in fibrosis scores were reflected in changes in liver hydroxyproline content and activation of hepatic stellate cells, which produce scar tissue material."These results demonstrate that coagulation status has a strong influence on hepatic fibrogenesis, " the investigators concluded. "These results represent the first reported use of anticoagulation to slow hepatic fibrogenesis and suggest a potential novel anti-fibrotic therapeutic approach for the future."Based on these findings, the investigators are starting a clinical trial of warfarin as an anti-fibrotic treatment for liver transplant recipients with hepatitis C, who are at risk for rapid fibrosis in the new liver due to HCV recurrence."If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take," said study coauthor Quentin Anstee in a media release issued by Imperial College London. "If we are successful in hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."Faculty of Medicine, Imperial College, London, UK; Southampton General Hospital, Southampton, UK; MRC Mammalian Genetics Unit, MRC Harwell, Oxfordshire, UK.

[Guest guest]

My sister who just turned 14 has colitis and she has had it all her life.

[Guest guest]

What is ESLD?

[Guest guest]

Mine started back in 85 , but started off ischemic with lots of rectal bleeding . I have already been hospitalized 2 times for it . They think because my heart rate drops so low that I am not getting enough oxygen to that portion of my large intestines ..

Re: Liz.. Ot

My sister who just turned 14 has colitis and she has had it all her life.

[Guest guest]

end stage liver disease

Re: Liz.. Ot

What is ESLD?